Sensei Biotherapeutics Toekomstige groei

Future criteriumcontroles 0/6

Sensei Biotherapeutics's winst zal naar verwachting dalen met 18.9% per jaar. De winst per aandeel zal naar verwachting dalen met 1.9% per jaar.

Belangrijke informatie

-18.9%

Groei van de winst

-1.9%

Groei van de winst per aandeel

Biotechs winstgroei	27.5%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	-59.8%
Dekking van analisten	Low
Laatst bijgewerkt	03 Oct 2024

Recente toekomstige groei-updates

Recent updates

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

Nov 03

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Jul 02

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Mar 14

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Aug 14

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Aug 09

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Apr 18

Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Nov 16

Winst- en omzetgroeiprognoses

NasdaqGM:SNSE - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	N/A	-44	N/A	-49	2
12/31/2025	N/A	-37	N/A	-40	2
12/31/2024	N/A	-31	N/A	-32	3
6/30/2024	N/A	-30	-24	-24	N/A
3/31/2024	N/A	-32	-28	-28	N/A
12/31/2023	N/A	-34	-32	-32	N/A
9/30/2023	N/A	-39	-36	-35	N/A
6/30/2023	N/A	-45	-38	-38	N/A
3/31/2023	N/A	-46	-40	-40	N/A
12/31/2022	N/A	-49	-39	-39	N/A
9/30/2022	N/A	-46	-38	-37	N/A
6/30/2022	N/A	-42	-37	-36	N/A
3/31/2022	N/A	-41	-32	-30	N/A
12/31/2021	N/A	-37	-32	-30	N/A
9/30/2021	N/A	-33	-27	-25	N/A
6/30/2021	N/A	-28	-28	-25	N/A
3/31/2021	N/A	-23	-24	-22	N/A
12/31/2020	N/A	-20	-19	-18	N/A
9/30/2020	N/A	-23	-18	-17	N/A
12/31/2019	N/A	-21	-9	-9	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat SNSE de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat SNSE de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat SNSE de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van SNSE naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er wordt verwacht dat SNSE volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat SNSE binnen 3 jaar verliesgevend zal zijn.

Sensei Biotherapeutics Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 13% to US$4.33

Price target decreased to US$8.00

Price target decreased to US$11.00

Recent updates

Sensei Biotherapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5450(a)(1)

Price target decreased by 13% to US$4.33

Sensei Biotherapeutics, Inc., Annual General Meeting, Jun 11, 2024

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

New minor risk - Share price stability

Sensei Biotherapeutics, Inc. Announces Management Changes

High number of new directors

Newtyn Partners, LP and Newtyn TE Partners, LP, managed by Newtyn Management, LLC cancelled the acquisition of remaining 93.48% stake in Sensei Biotherapeutics, Inc. (NasdaqGM:SNSE).

Sensei Biotherapeutics, Inc. Appoints Stephanie Krebs, Ms, Mba, as Chief Business Officer

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

Sensei Biotherapeutics, Inc. Appoints Stephanie Krebs, Ms, Mba, as Chief Business Officer

Sensei Biotherapeutics, Inc. to Present Initial Clinical Data from Dose Escalation Trial of SNS 101 At 2023 SITC Annual Meeting

Sensei Biotherapeutics Receives Non-Compliance Notice from Nasdaq

Sensei Biotherapeutics Receives Non-Compliance Notice from Nasdaq

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo

Sensei Biotherapeutics, Inc. Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Sensei Biotherapeutics, Inc., Annual General Meeting, Jul 10, 2023

Sensei Biotherapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101

Sensei Biotherapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

High number of new directors

eSensei Biotherapeutics, Inc. Announces Reduction of Total Workforce

Sensei Biotherapeutics, Inc. Announces Executive Changes

High number of new and inexperienced directors

Sensei Biotherapeutics, Inc. Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Apeiron Investment Sends a Letter to Sensei Biotherapeutics

Sensei Biotherapeutics, Inc. Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

Sensei Biotherapeutics, Inc. Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, A Ph-Selective Vista-Blocking Antibody

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Sensei Biotherapeutics, Inc.(NasdaqGM:SNSE) dropped from Russell 2500 Value Index

Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer

Price target decreased to US$8.00

High number of new and inexperienced directors

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Price target decreased to US$11.00

Chairman of The Board recently bought US$80k worth of stock

Chairman of The Board recently bought US$136k worth of stock

Chairman of The Board recently bought US$53k worth of stock

Independent Director recently bought US$57k worth of stock

Independent Director recently bought US$250k worth of stock

Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Chief Scientific Officer recently sold US$568k worth of stock

Sensei Biotherapeutics, Inc.(NasdaqGM:SNSE) dropped from Russell 3000E Growth Index

Sensei Biotherapeutics, Inc. Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck

Sensei Biotherapeutics, Inc. announced that it has received $34.5 million in funding from a group of investors

Independent Director recently bought US$143k worth of stock

Independent Director recently bought US$233k worth of stock

Sensei Biotherapeutics Appoints Deneen Vojta to the Board of Directors

Sensei Biotherapeutics, Inc. has completed an IPO in the amount of $133.000988 million.

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven